Table 2.
Acute In Vivo Tests for Aberrant Receptors
| Acute In Vivo Tests for Aberrant Receptors | Plasma Cortisol Basal (μg/dL) | Plasma Cortisol Maximum (μg/dL) | % Increase |
|---|---|---|---|
| Orthostasis | 10.8 | 13.9 | 28.7 |
| Test meal | 5.8 | 8.6 | 48.3 |
| ACTH, 0.25 mg intramuscularly | 9.2 | 22.4 | 143.5 |
| GnRH, 200 μg intravenously | 18.2 | 16.3 | −10.4 |
| Thyrotropin-releasing hormone, 200 μg intravenously | 5.0 | 7.2 | 44.0 |
| Glucagon, 1 mg intramuscularly | 5.6 | 7.0 | 25.0 |
| DEXA, 0.5 mg orally/AVP, 10 IE intramuscularly | 0.1 | 3.1 | 3000.0 |
| Metoclopramide, 10 mg orally | 1.1 | 1.2 | 9.1 |
Results of standardized in vivo screening tests for the presence of ectopic or overexpressed eutopic adrenal hormone receptors in the patient with CS are shown. Responses to the various stimuli were considered “positive” if there was a cortisol increase >50% of basal, “partial” with a response between > 25% and < 50%, and “negative” when <25%.
Abbreviation: DEXA, dexamethasone.